Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$69.85
pos +0.00
+0.00%
Today's Range: 69.71 - 70.79 | GILD Avg Daily Volume: 10,720,200
Last Update: 02/17/17 - 4:00 PM EST
Volume: 0
YTD Performance: -2.46%
Open: $0.00
Previous Close: $70.31
52 Week Range: $65.38 - $103.10
Oustanding Shares: 1,310,000,000
Market Cap: 92,106,100,000
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 12 10
Moderate Buy 1 1 1 1
Hold 8 8 8 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.85 1.85 1.81 1.95
Latest Dividend: 0.52
Latest Dividend Yield: 2.96%
Dividend Ex-Date: 03/14/17
Price Earnings Ratio: 7.07
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
7.07 7.10 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.58% -21.83% -13.99%
GROWTH 12 Mo 3 Yr CAGR
Revenue 31.10 1.70 0.39
Net Income -25.50 3.40 0.63
EPS -16.50 4.00 0.70
Earnings for GILD:
EBITDA 17.63B
Revenue 30.39B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $2.15 $2.09 $8.22 $7.62
Number of Analysts 7 6 9 3
High Estimate $2.30 $2.22 $10.01 $8.40
Low Estimate $1.98 $1.99 $7.32 $6.80
Prior Year $2.98 $3.03 $11.37 $8.22
Growth Rate (Year over Year) -27.85% -30.97% -27.68% -7.30%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Takeaways and Observations Real Money Pro($)

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. 
Some tried-and-true indicators show what's really going on with the market.

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.
Don't fight the trend of this stock.

Takeaways and Observations Real Money Pro($)

 
Static doesn't work in this industry. Pipelines work.
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences (GILD)  is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro (TSRO) , which is currently halted and might be the next oncology concern to receive a buyout offer. Clovis Oncology (CLVS)  is rising in empathy as it has also been a much-rumored acquisition target in this hot space.

Scanning the Biotech Universe Real Money Pro($)

Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers and acquisitions to acquire some growth, I don't know what will. Gilead did end the quarter with more than $30 billion in cash on hand, so it definitely has the financial firepower to do so should it choose. Until then, stock is at best dead money.
I'm glad to be sitting in for Doug Kass on the Daily Diary over the next two days. There is plenty to talk about. Because we are the heart of earnings season, let's start with the quarterly results from two well-known large-cap concerns.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.